Wilcrest Pharmaceuticals, Inc. has secured a national group purchasing agreement for Outsourced Compounded Preparations with Premier, Inc., effective April 1, 2026. This partnership enables Premier members to access pre-negotiated pricing and terms for compounded medications, enhancing the availability of these critical therapies across thousands of health systems in the U.S. A.J. Day, PharmD, CEO of Wilcrest Pharma, emphasized the company’s commitment to addressing persistent clinical and operational challenges in healthcare, particularly where viable treatment options are lacking.

The significance of this agreement lies in its potential to improve patient access to compounded therapies, which are often essential for individualized treatment plans. Wilcrest Pharma, as an FDA-registered 503B outsourcing facility, specializes in the formulation of both hazardous sterile and nonsterile medications. By leveraging Premier’s extensive network and analytics capabilities, Wilcrest aims to streamline medication access and reduce the compounding burden on healthcare providers. This collaboration aligns with the broader trend of integrating technology and data-driven solutions to enhance healthcare delivery.

The implications of this partnership extend to the field of longevity science and healthspan research. As Wilcrest Pharma focuses on operationally challenging medications, this agreement may accelerate the development and availability of innovative therapies that target age-related conditions. By facilitating easier access to compounded medications, the collaboration could shorten drug development timelines and foster a more responsive approach to emerging health challenges in aging populations. This strategic move underscores the importance of partnerships in advancing therapeutic options and improving patient outcomes in the evolving landscape of healthcare.

Source: globenewswire.com